NEW YORK (GenomeWeb) – Epigenomics announced today that it has received CE-IVD marking for its blood-based lung cancer test Epi proLung.

Epi proLung searches for a combination of DNA methylation biomarkers in order to detect cancer, the company said. The assay was partly developed with funding from the European Commission within the framework of the Horizon 2020 program.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.